Non-Hodgkin Lymphoma INCB 50465-203

The purpose of this study is to assess the objective response rate of INCB050465 treatment in subjects with relapsed or refractory follicular lymphoma.

Eligibility Criteria:

  1. Histologically confirmed, relapsed or refractory, follicular B-cell NHL (follicular lymphoma) Grade 1, 2, and 3a.
  2. Ineligible for hematopoietic stem cell transplant.
  3. Must have been treated with at least 2 prior systemic therapies.
  4. Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures > 1.5 cm in the longest dimension and ≥ 1.0 cm in the longest perpendicular dimension as assessed by computed tomography or magnetic resonance imaging.

This study is for patients age 18 and older.

Available at: Hospital of Central Connecticut

Cancer Clinical Research Office